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Abstract
Introduction: Breast cancers of different molecular subtypes have different survival rates. The goal of this study
was to identify patients at high risk for local-regional recurrence according to response to neoadjuvant
chemotherapy and surrogate markers of molecular subtypes in patients undergoing breast conserving therapy
(BCT).
Methods: Clinicopathologic data from 595 breast cancer patients who received neoadjuvant chemotherapy and
BCT from 1997 to 2005 were identified. Estrogen receptor (ER), progesterone receptor (PR) and human epidermal
growth factor receptor 2 (HER2) expression determined by immunohistochemistry were used to construct the
following subtypes: ER+ or PR+ and HER2- (hormone receptor (HR)+/HER2-; 52%), ER+ or PR+ and HER2+ (HR
+/HER2+; 9%), ER- and PR- and HER2+ (HR-/HER2+; 7%) and ER- and PR- and HER2- (HR-/HER2-; 32%). Actuarial
rates were calculated using the Kaplan-Meier method and compared using the log-rank test. Cox proportional
hazards models were used for multivariate analysis (MVA).
Results: After a median follow-up of 64 months, the five-year local-regional recurrence (LRR)-free survival rate for
all patients was 93.8%. The five-year LRR-free survival rates varied by subtype: HR+/HER2- 97.0%, HR+/HER2+ 95.9%,
HR-/HER2+ 86.5% and HR-/HER2- 89.5% (P = 0.001). In addition to subtype, clinical stage III disease (90% vs. 95% for
I/II, P = 0.05), high nuclear grade (92% vs. 97% with low/intermediate grade, P = 0.03), presence of lymphovascular
invasion (LVI) (89% vs. 95% in those without LVI, P = 0.02) and four or more positive lymph nodes on pathologic
examination (87% vs. 95% with zero to three positive lymph nodes, P = 0.03) were associated with lower five-year
LRR-free survival on univariate analysis. On MVA, HR-/HER2+ and HR-/HER2- subtypes and disease in four or more
lymph nodes were associated with decreased LRR-free survival. A pathologic complete response (pCR) was
associated with improved LRR-free survival.
Conclusions: Patients with HR+/HER2- and HR+/HER2+ subtypes had excellent LRR-free survival regardless of
tumor response to neoadjuvant chemotherapy. Patients with HR-/HER2+ and HR-/HER2- subtypes with poor
response to neoadjuvant chemotherapy had worse LRR-free survival after BCT. Additional study is needed to
determine the impact of trastuzumab on local-regional control in HER2+ tumors. Our data suggest that patients
with HR-/HER2- subtype tumors not achieving pCR may benefit from novel strategies to improve local-regional
control.
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Introduction
The local-regional management of breast cancer has
evolved significantly over the past several decades. Based
on data from prospective studies, breast conservation
therapy (BCT), defined as lumpectomy with whole
breast irradiation, is now accepted as oncologically
equivalent to mastectomy in terms of overall survival
(OS) [1-6]. The number of patients who are candidates
for BCT has increased with the use of neoadjuvant che-
motherapy, which has been shown to downsize tumors,
facilitating BCT in patients that would otherwise require
mastectomy if surgery were performed first [7-9].
Numerous clinical trials have investigated the impact of
neoadjuvant versus adjuvant chemotherapy on survival
and two meta-analyses have reported equivalent out-
comes [10,11]. The use of neoadjuvant chemotherapy
has also allowed insight into tumor biology and differen-
tial response to treatment. Studies have shown that
estrogen receptor (ER)-negative and high-grade tumors
are more likely to respond to neoadjuvant chemotherapy
[12-14]. In addition, multiple previous reports have
demonstrated that achieving a pCR with neoadjuvant
chemotherapy is associated with improved overall survi-
val (OS) [9,15-17]. The effects of response to neoadju-
vant chemotherapy on local-regional control are less
well studied.
The importance of the underlying biology of breast
tumors in predicting outcomes has been demonstrated
by microarray analyses that identified molecular sub-
types. The subtypes were initially defined by gene
expression profiles that broadly divided breast tumors
into subgroups, including: ER positive/luminal-like,
basal-like, HER2 positive and normal breast [18]. Subse-
quent studies demonstrated that the ER positive/lumi-
nal-like group could be further refined into two
subgroups; luminal A and luminal B with luminal A
having greater expression of ER-related genes and lumi-
nal B having higher expression of proliferative genes
[19,20]. These classifications were determined to be
clinically relevant when it was demonstrated that there
were significant differences in survival based on the sub-
type. ER/luminal tumors had longer disease-free and OS
while basal-like and HER2 subtypes had worse outcomes
[19].
Although determination of molecular subtype may be
the most accurate way to evaluate breast cancers, such
molecular profiling is currently not feasible for routine
clinical care due to the time, cost and resources
required to perform the analysis. In addition, it has not
yet been demonstrated that decisions regarding local-
regional or systemic treatment options should be made
based on molecular subtyping. Therefore, clinicians have
used hormone receptor and HER2 status, which are
routinely provided in a patient’s pathology report, to
group tumors into constructed subtypes [21,22]. These
constructed subtypes, which have been approximated as
luminal A (ER+ or progesterone receptor (PR)+, HER2-
), luminal B (ER+ or PR+, HER2+), HER2 (ER-, PR-,
HER2+) and basal (ER-, PR-, HER2-), have been shown
to approximate the molecular subtype signatures [23].
In a study evaluating almost 800 patients, Nguyen et al.
reported that local recurrence rates following BCT in
patients undergoing surgery as a first intervention varied
according to subtype approximated using ER, PR and
HER2 status [24]. Because neoadjuvant chemotherapy is
increasingly used in breast cancer patients to facilitate
BCT and because response to neoadjuvant chemother-
apy has been shown to provide prognostic information,
we undertook the current study to determine if categor-
izing patients into subgroups using ER, PR and HER2
status could predict response to neoadjuvant che-
motherapy and identify patients at high risk for local-




A prospectively maintained database was used to iden-
tify patients with non-metastatic breast cancer who
received neoadjuvant chemotherapy followed by BCT
from 1997 to 2005. The study was approved by the Uni-
versity of Texas MD Anderson Cancer Center Institu-
tional Review Board. Clinicopathologic data were
recorded, including: clinical T and N stage according to
the sixth edition of the American Joint Committee on
Cancer staging guidelines, pathologic tumor size, num-
ber of lymph nodes identified pathologically, Black’s
modified nuclear grade, presence of lymphovascular
invasion (LVI), ER, PR and HER2 status. Clinical T and
N stage were determined at presentation by physical
examination, mammography and ultrasound (US) of the
breast and regional nodal basins. Lymph nodes appear-
ing abnormal on US were routinely evaluated by fine
needle aspiration biopsy [25]. For hormone receptor sta-
tus, > 10% staining of cells by immunohistochemistry
(IHC) was considered positive. Tumors were considered
HER2-positive if they were 3+ by IHC or demonstrated
gene amplification by fluorescence in situ hybridization.
A pCR was defined as no residual invasive disease in the
breast or axilla.
The study population of 595 patients was made up of
patients for whom ER, PR and HER2 status was known.
ER and PR status were categorized as hormone receptor
(HR) positive if ER or PR staining was positive and HR
negative if ER and PR staining were negative. These
patients were then categorized based on their
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constructed subtype as follows: HR+/HER2- (ER+ or PR
+ and HER2-), HR+/HER2+ (ER+ or PR+ and HER2+),
HR-/HER2+ (ER- and PR- and HER2+) and HR-/HER2-
(ER- and PR- and HER2-).
Treatment
All patients received neoadjuvant chemotherapy consist-
ing of an anthracycline (98%), taxane (84%) or a combi-
nation of the two. Because this study predated the
routine use of neoadjuvant trastuzumab therapy,
patients receiving neoadjuvant trastuzumab were
excluded. Following neoadjuvant chemotherapy, all
patients underwent BCT, including lumpectomy, axillary
node evaluation and whole breast irradiation. At MD
Anderson we have developed a standard approach
whereby all patients undergo imaging before and after
chemotherapy (diagnostic mammography and ultra-
sound). The ultrasound evaluation includes the breast
and regional nodal basins. Any suspicious appearing
lymph nodes are confirmed to be positive for metastasis
by fine needle aspiration biopsy. A marking clip is
placed at the tumor site early in the treatment course to
facilitate resection of the primary tumor bed in case of
complete radiographic response. Following neoadjuvant
chemotherapy, any residual radiographic abnormality
and the clip are targeted for resection along with at
least a 2 mm margin of normal tissue. In most cases, we
do not attempt to excise the entire pre-chemotherapy
tumor volume [26-28]. Patients with positive margins at
initial attempt at BCT who were then converted to mas-
tectomy were excluded from this study. For patients
presenting with clinically node negative disease, axillary
evaluation consisted of sentinel lymph node (SLN) dis-
section with completion axillary lymph node dissection
(ALND) performed when the SLN showed metastatic
disease. Patients presenting with clinically node positive
disease underwent ALND. Radiation included external-
beam therapy to the whole breast with tangential fields.
Standard treatment included a 50 Gy median dose to
the breast delivered over five weeks in 25 fractions fol-
lowed by a boost to the tumor bed (10 Gy median
dose). Regional nodal irradiation (RNI) was administered
at the discretion of the radiation oncologist and was
generally considered for patients with clinical stage III
disease, those with residual positive lymph nodes identi-
fied pathologically and selectively for other indications
to include young age, residual tumor > 2 cm, LVI and
pretreatment extent of disease on US. Patients with hor-
mone receptor positive disease were routinely offered
adjuvant endocrine therapy.
Endpoints and statistical methods
The primary endpoint was LRR defined as disease recur-
rence in the ipsilateral breast or the axillary,
supraclavicular, infraclavicular or internal mammary
lymph nodes. All LRRs were considered events regard-
less of whether they were the first site of failure or
occurred with or after distant metastasis. Patients who
did not experience a LRR were censored at last follow-
up or at the time of death.
Distributions of clinical factors between groups were
compared using the Kruskal-Wallis test for continuous
variables and chi-squared test for categorical variables.
Actuarial rates of LRR were calculated using the
Kaplan-Meier method and differences between groups
were compared using the log-rank test. Multivariate
analyses were performed using a Cox proportional
hazards model. All calculations were performed with
Stata software (Stata/SE 11; Stata Corp., College Station,
TX, USA). Two-tailed P-values ≤ 0.05 were considered
statistically significant.
Results
The study population consisted of 595 patients who
received neoadjuvant chemotherapy and then under-
went BCT; 309 (52%) categorized as HR+/HER2-, 51
(9%) HR+/HER2+, 42 (7%) HR-/HER2+, and 193 (32%)
HR-/HER2-. Table 1 lists clinicopathologic characteris-
tics by constructed subtype. There were significant dif-
ferences in the distribution of clinical N stage (P =
0.04) between the subtypes, driven largely by HR-/
HER2+ patients being less likely to have clinical N0
disease. There was also a significant difference (P <
0.001) with respect to nuclear grade with patients in
the HR-/HER2+ and HR-/HER2- groups having a
higher percentage of patients with grade 3 disease.
When evaluating response to neoadjuvant chemother-
apy, we noted a difference (P < 0.001) in pCR rates
with a lower percentage of patients in the HR+/HER2-
(9%) and HR+/HER2+ (18%) subgroups achieving a
pCR compared with patients in the HR-/HER2+ (36%)
and HR-/HER2- (38%) subgroups. Patients with HR-/
HER2+ and HR-/HER2-tumors had smaller pathologic
tumor sizes and a greater proportion had fewer than
four positive lymph nodes identified at pathologic eva-
luation after surgery.
Median follow-up for the entire study population was
64 months (range 4 to 136 months). There were 24
local recurrences and 11 regional recurrences and the
five-year LRR-free survival rate for the entire population
was 93.8%. The five-year LRR-free survival rate was
higher for HR+/HER2- and HR+/HER2+ patients when
compared to HR-/HER2+ or HR-/HER2- patients
(97.0%, 95.9%, 86.5%, 89.5%, respectively, P = 0.001)
(Figure 1). The distribution of local versus regional
recurrences by subtype is shown in Table 2. The five-
year overall survival (OS) rate for the entire population
was 88.2%. The five-year OS rates by subtype were: HR
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+/HER2- 92.5%, HR+/HER2+ 85.8%, HR-/HER2+ 84.4%,
and HR-/HER2- 83.0% (P = 0.008).
In addition to constructed subtype, we also evaluated
the effect of other clinical and pathologic features on
LRR-free survival rates. As shown in Table 3 clinical
stage III disease, four or more positive lymph nodes,
presence of LVI and high nuclear grade were all signifi-
cantly associated with lower LRR-free survival rates on
univariate analysis. In order to determine the impact of
these factors based on subtype, analyses were repeated
with patients divided by constructed subtype (Table 4).
Among patients who did not achieve a pCR or who had






















T0 1 (0.3%) 0 0 0
T1 65 (21%) 5 (10%) 6 (14%) 19 (10%)
T2 207 (67%) 36 (70%) 33 (79%) 140 (73%)
T3 25 (8%) 5 (10%) 3 (7%) 22 (11%)
T4 10 (3%) 5 (10%) 0 12 (6%)
Tx 1 (0.3%) 0 0 0
Clinical N-stage 0.03
N0 167 (54%) 29 (57%) 11 (26%) 101 (52%)
N1 110 (36%) 15 (29%) 23 (55%) 62 (32%)
N2 12 (4%) 1 (2%) 4 (9.5%) 9 (5%)
N3 20 (6%) 6 (12%) 4 (9.5%) 21 (11%)
Clinical stage 0.18
I 26 (8%) 4 (8%) 2 (5%) 8 (4%)
II 234 (76%) 35 (69%) 30 (71%) 137 (71%)
II 50 (16%) 12 (23%) 10 (24%) 48 (25%)
Nuclear grade < 0.001
1 15 (5%) 1 (2%) 0 0
2 144 (47%) 14 (28%) 3 (7%) 21 (11%)
3 149 (48%) 36 (70%) 39 (93%) 172 (89%)
Unknown 1 (0.3%) 0 0 0
LVI 0.47
Yes 55 (18%) 5 (10%) 7 (17%) 28 (15%)
No 254 (82%) 46 (90%) 35 (83%) 165 (85%)











Number positive lymph nodes
0 152 (49%) 34 (67%) 27 (64%) 149 (77%) < 0.001
1-3 103 (33%) 9 (18%) 11 (26%) 32 (17%)
≥ 4 53 (17%) 6 (12%) 4 (10%) 12 (6%)
Unknown 1 (0.3%) 2 (3%) 0 0












Yes 27 (9%) 9 (18%) 15 (36%) 73 (38%)
No 282 (91%) 42 (18%) 27 (64%) 120 (62%)
*The Kruskal-Wallis test was used for age (continuous variable). All other P-values were determined using the c2 test for equality of distributions. LVI,
lymphovascular invasion; pCR, pathologic complete response
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four or more positive lymph nodes, those who were
HR-/HER2+ and HR-/HER2- had decreased five-year
LRR-free survival, while HR+/HER2-and HR+/HER2+
patients continued to have high rates of LRR-free survi-
val. For example, the five-year LRR-free survival rate for
patients categorized as HR-/HER2-that achieved a pCR
was 99%, whereas in those who did not achieve a pCR,
the five-year LRR-free survival rate was 84%. In contrast,
for patients with HR+/HER2-disease, the five-year LRR-
free survival rate was 96% for those who achieved a pCR
and 97% for those who did not. Similarly, for patients
that had four or more positive lymph nodes, the five-
year LRR-free survival rate for patients with HR-/HER2-
tumors was 56%, versus 91% if they had zero to three
positive lymph nodes. For patients with HR+/HER2- dis-
ease, the five-year LRR-free survival rates were 93% and
98%, respectively, for those who had four or more posi-
tive lymph nodes versus those who had zero to three
positive nodes.
A multivariate analysis was performed that included
constructed subtype, clinical stage, grade, presence or
absence of LVI, pCR versus no pCR and number of
positive lymph nodes dichotomized as zero to three ver-
sus four or more. Using HR+/HER2- as the referent,
HR-/HER2+ (Hazard ratio 5.7, 95% CI: 2.0 to 16.3, P =
0.001) and HR-/HER2- (Hazard ratio 5.7, 95% CI: 2.6 to
112.3, P < 0.001) subtypes were associated with reduced
LRR-free survival. Disease in four or more lymph nodes
Figure 1 Local-regional recurrence free survival by constructed subtype. Actuarial rates of local-regional recurrence were calculated using
the Kaplan-Meier method and differences between groups were compared using the log-rank test.










Local 4 2 4 14
Regional 4 1 1 5
Table 3 Five-year actuarial rates of local-regional control
according to clinical and pathological disease status
Factor 5-year LRC rate P-value
Clinical Stage
I/II (n = 475) 95% 0.05
III (n = 120) 90%
Number positive nodes*
0 to 3 (n = 517) 95% 0.03
≥ 4 (n = 75) 87%
pCR
No (n = 471) 93% 0.06
Yes (n = 124) 97%
LVI
No (n = 500) 95% 0.02
Yes (n = 95) 89%
Nuclear grade**
1 or 2 (n = 198) 97% 0.03
3 (n = 396) 92%
* In three patients the number of lymph nodes was unknown. ** In one
patient, the nuclear grade was unknown. LRC, local-regional control; LVI,
lymphovascular invasion; pCR, pathologic complete response
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(Hazard ratio 2.9, 95% CI: 1.3 to 6.6, P = 0.01) was also
independently associated with decreased LRR-free survi-
val. Achieving a pCR (Hazard ratio 0.22 (0.07 to 0.74, P
= 0.014) was associated with improved LRR-free survival
(Table 5).
Discussion
The recognition that breast cancer is a heterogeneous
disease with tumors of different molecular subtypes
being driven by different biologic pathways, having dif-
ferent response to therapy and different survival rates,
has been an important advance [18,19,29]. These sub-
types, including luminal A, luminal B, HER2 and basal,
were initially identified using cDNA microarray analysis.
Subsequently, investigators have demonstrated that con-
structed molecular subtypes determined using ER, PR
and HER2 status corresponds with these molecular sub-
types thus allowing clinicians to apply this concept to
patient care and decision making [30]. In the current
study, we have determined the constructed subtype for a
large population of patients that received neoadjuvant
chemotherapy and then underwent BCT. We found that
the constructed subtype correlated both with response
to neoadjuvant chemotherapy as well as LRR-free survi-
val. Importantly, patients with HR+/HER2- and HR
+/HER2+ subtypes had excellent rates of LRR-free survi-
val regardless of tumor response to neoadjuvant che-
motherapy. In contrast, in patients with HR-/HER2-
subtypes, the response to neoadjuvant chemotherapy
was more likely to predict LRR-free survival, with those
who responded poorly to neoadjuvant chemotherapy,
having worse local-regional control after BCT.
Other groups have evaluated the impact of con-
structed subtypes on local-regional control in different
patient populations. An early study addressing this ques-
tion by Nguyen et al., evaluated 793 patients treated
with BCT as a first intervention between 1998 and 2001
[24]. Ninety percent of patients in their series received
systemic therapy. After a median follow-up of 70
months, the five-year incidence of LRR was 0.8% for
what these investigators referred to as luminal A (HR
+/HER2-), 1.5% for luminal B (HR+/HER2+), 8.4% for
HER2 (HR-/HER2+) and 7.1% for basal (HR-/HER2-)
tumors. Similar to the findings from the current study,
on multivariate analysis using HR+/HER2- as the refer-
ent, the HR-/HER2+ and HR-/HER2- subtypes were
associated with higher rates of LRR. A recent publica-
tion from Arvold et al. also evaluated differences in LRR
based on constructed subtypes in a population of
patients undergoing BCT [31]. In contrast to the study
by Nguyen et al., which was limited to patients under-
going initial surgery, and to our study, which was












I/II (n = 473) 98% 95% 86% 91% 0.004
III (n = 120) 92% 100% 89% 84% 0.25
Number positive nodes*
0 to 3 (n = 517) 98% 95% 89% 91% 0.007
≥ 4 (n = 75) 93% 100% 67% 56% 0.001
pCR
No (n = 471) 97% 95% 83% 84% < 001
Yes (n = 124) 96% 100% 92% 99% 0.62
LVI
No (n = 500) 97% 95% 83% 93% 0.007
Yes (n = 95) 96% 100% 100% 70% 0.001
Nuclear grade**
1 or 2 (n = 197) 97% 100% 67% 100% 0.009
3 (n = 395) 97% 94% 88% 88% 0.04
* In three patients the number of lymph nodes was unknown. ** In one patient, the nuclear grade was unknown. LRC, local-regional control; LVI, lymphovascular
invasion; pCR, pathologic complete response
Table 5 Multivariate analysis of factors associated with
local-regional control
Factor Hazard Ratio (95% CI) P-value
Subtype*
HR-/HER2- 5.7 (2.6 to 12.3) < 0.001
HR-/HER2+ 5.7 (2.0 to 16.3) 0.001
≥ 4 positive lymph nodes 2.9 (1.3 to 6.6) 0.01
pCR 0.22 (0.07 to 0.74) 0.01
* HR+/HER2- used as referent. CI, confidence interval; pCR, pathologic
complete
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limited to patients receiving neoadjuvant chemotherapy,
the Arvold study included BCT patients regardless of
whether they received neoadjuvant chemotherapy, adju-
vant chemotherapy or no chemotherapy (46% of patients
did receive systemic treatment). These investigators clas-
sified patients based on receptor status as well as
nuclear grade with subgroups defined as luminal A (ER
or PR+, HER2 -, grade 1 to 2), luminal B (ER or PR+,
HER2 -, grade 3), luminal HER2 (ER or PR+, HER2+),
HER2 (ER/PR-, HER2+), and triple negative (ER/PR-,
HER2-). The five-year LRR rates were 0.8% for luminal
A, 2.3% for luminal B, 1.1% for luminal HER2, 10.8% for
HER2 and 6.7% for triple negative [32]. In this case,
using constructed molecular subtypes, in addition to
grade, they were able to classify patients based on rates
of local-regional control. Investigators from the Univer-
sity of North Carolina used constructed molecular sub-
types to predict local-regional control in 149 patients
treated between 1991 and 2005 [33]. Similar to our
study, they included only patients who received neoadju-
vant chemotherapy; however, patients could undergo
BCT or mastectomy. After a median follow-up of 55
months, they reported a higher rate of LRR in patients
with HR-/HER2- tumors (14%) versus HR+/HER2- (4%),
HR+/HER2+ (4%), or HR-/HER2+ (5%) (P = 0.03). This
study also predated the routine use of trastuzumab in
patients with HER2-overexpressing disease. Evaluating
just those patients who underwent BCT (n = 49), they
noted that there were no LRR events in the HR+/HER2-
, HR+/HER2+, or HR-/HER2+ groups while 8% of the
HR-/HER2- group developed LRR (P = 0.99) [33]. These
data are limited by the small number of patients but
their findings are consistent with the current study
showing excellent rates of local-regional control for
patients with HR+ breast cancer.
The current study represents the largest series evaluat-
ing the effect of subtype on response to neoadjuvant
chemotherapy and LRR-free survival in patients under-
going BCT. We found that patients with HR+/HER2-
and HR+/HER2+ tumors had significantly lower rates of
pCR (9% and 18%, respectively) compared with patients
with HR-/HER2+ or HR-/HER2- tumors (36% and 38%,
respectively). This is consistent with recently published
data from the I-SPY 1 TRIAL, a multicenter study eval-
uating patients with tumors ≥ 3 cm using molecular sig-
natures and early imaging with outcomes of pCR and
recurrence free survival (RFS) [34]. In the I-SPY trial,
the pCR rate was 9% in patients with HR positive
tumors, which is identical to our rate for HR+/HER2-
tumors. For patients with HR-/HER2- tumors, the pCR
rate was 35%, comparable to our 38% rate. One differ-
ence between these studies was the pCR rate of 54% in
HR-/HER2+ patients in the I-SPY 1 trial; higher than
our rate of 36% but based on only 13 patients.
Guarneri et al. previously reported that patients with
ER-negative tumors were more likely to achieve a pCR
after neoadjuvant chemotherapy [14]. The study by
Guarneri and the current study do have some overlap
in the population of patients reported; however, the
previous report included patients that underwent mas-
tectomy as well as BCT. Guarneri noted that patients
with ER-positive tumors, despite having lower rates of
pCR, had better five-year overall and progression-free
survival rates. We found similar results in patients
with HR+/HER2- and HR+/HER2+ disease, regardless
of whether they responded to neoadjuvant chemother-
apy. For patients with HR+/HER2- disease who
achieved a pCR, the five-year LRR-free survival rate
was 96% versus 97% for those who did not have a
pCR. Similarly, for patients with HR+/HER2+ disease,
the five-year LRR-free survival rates were 100% and
95%, respectively for those who did and did not have a
pCR. These data likely reflect both the overall favor-
able biology of the HR+ subtypes as well as the effec-
tiveness of hormonal therapy in these patients. In
contrast, for patients with HR-/HER2- tumors, we
found a high rate of pCR (38%) and whether or not a
patient achieved a pCR had significant implications for
LRR-free survival rates. Patients who achieved a pCR
had a five-year LRR-free survival rate of 99% versus
84% in those who did not achieve a pCR. Our data are
again consistent with recently published data from the
I-SPY 1 TRIAL, where they found that the association
between RFS and pCR was greatest for patients who
did not have HR+/HER2- tumors [34]. The use of
neoadjuvant chemotherapy in patients with HR-/
HER2- tumors could, therefore, be useful in helping to
identify patients at higher risk of LRR. For patients
with HR-/HER2- tumors who fail to achieve a pCR,
particularly those with four or more positive lymph
nodes identified at the time of surgery, strategies to
improve local-regional control should be explored
including mastectomy or the use of radio-sensitizers to
enhance the effects of radiation in BCT patients. The
identification and evaluation of radio-sensitizers is a
relevant consideration as data from the Danish Breast
Cancer Cooperative Group suggests that this pheno-
type may be less responsive to radiotherapy [35].
An important limitation of our study is the ability to
draw meaningful conclusions for patients with HER2
positive tumors. This is because of the small number of
patients included with HER2+ subtypes (n = 93, 51 HR
+/HER2+ and 42 HR-/HER2+), as well as the fact that
the study period predated the routine use of trastuzu-
mab in either the adjuvant or neoadjuvant setting. The
addition of trastuzumab to adjuvant chemotherapy has
been shown to improve disease free and OS in HER2-
positive patients [36-38]. The addition of trastuzumab
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to neoadjuvant chemotherapy regimens has had a signif-
icant impact as well. Studies looking at anthracycline-
based neoadjuvant chemotherapy that would have
included patients with HER2-positive tumors showed
pCR rates of approximately 13% [39]. The addition of
taxanes to anthracyclines improved pCR rates to 26 to
28% [39,40]. The addition of trastuzumab to neoadju-
vant chemotherapy regimens for patients with HER2-
positive disease has increased pCR rates to as high as
67% [41]. None of the patients with HER2+ tumors in
the current study received trastuzumab as part of their
neoadjuvant chemotherapy regimen and the pCR rate
was 18% for the HR+/HER2+ subgroup and 36% in the
HR-/HER2+ subgroup. We did not see significant differ-
ences in five-year LRR-free survival rates for patients
with HER2+ tumors based on whether they achieved a
pCR or not. This is likely attributable to the small num-
ber of patients. We did, however, note a difference in
local-regional control in the HR-/HER2+ group based
on the number of positive lymph nodes identified at the
time of surgery with patients with zero to three positive
lymph nodes having an 89% five-year LRR-free survival
rate versus 67% for those with four or more positive
nodes. Trastuzumab containing neoadjuvant chemother-
apy regimens have been shown to eradicate clinically
node positive disease in 74% of patients [42]. Taken
together, this suggests that the use of trastuzumab-con-
taining neoadjuvant chemotherapy regimens for patients
presenting with clinically node positive, HER2-overex-
pressing breast cancer could provide important informa-
tion regarding prognosis based on the extent of residual
disease. In addition, similar to patients with HR-/HER2-
tumors, failing to eradicate nodal disease with the use
of trastuzumab-based neoadjuvant chemotherapy could
identify a population who may benefit from radio-sensi-
tizers to enhance the response to therapy. Future stu-
dies with a larger cohort of patients treated with more
contemporary chemotherapy regimens incorporating
trastuzumab will be required to better determine the
effects of pCR on LRC in patients with HER2-positive
disease.
Conclusions
In summary, we have shown that constructed subtypes
can predict response to neoadjuvant chemotherapy as
well as LRR-free survival rates. Patients with HR positive
tumors have a low risk of local-regional failure regard-
less of tumor response to neoadjuvant chemotherapy. In
contrast, in patients with HR-/HER2- tumors, the
response to therapy has important implications for the
risk of LRR and may help to identify patients who may
benefit from novel strategies to improve local-regional
control.
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